In patients with recurrent or metastatic oropharyngeal squamous cell carcinoma who are not candidates for curative surgery or radiation, what is the role of cetuximab (Erbitux) as a palliative systemic therapy?

Role of Cetuximab in Palliative Oropharyngeal Cancer

Cetuximab combined with platinum-based chemotherapy (EXTREME regimen) is the standard first-line palliative treatment for recurrent/metastatic oropharyngeal cancer in patients whose tumors do not express PD-L1 (CPS <1) or who have contraindications to immunotherapy. For PD-L1-positive tumors (CPS ≥1), pembrolizumab-based regimens have superseded cetuximab as first-line therapy based on superior overall survival.

First-Line Treatment Algorithm

For PD-L1-Positive Tumors (CPS ≥1)

• Pembrolizumab monotherapy is preferred when rapid tumor shrinkage is not urgently needed 1
• Pembrolizumab + platinum/5-FU is preferred for symptomatic patients requiring rapid tumor response 1
• Both regimens achieved Level I, Grade A evidence with ESMO-MCBS score of 4

For PD-L1-Negative Tumors (CPS <1) or Immunotherapy Contraindications

Platinum/5-FU/cetuximab (EXTREME regimen) remains the standard therapy 1

• Level I, Grade A evidence with ESMO-MCBS score of 3
• Median overall survival: 10.1 months vs 7.4 months with chemotherapy alone 2
• Median progression-free survival: 5.6 months vs 3.3 months 2
• Objective response rate: 36% vs 20% 2

Alternative option: TPeX (cisplatin/docetaxel/cetuximab) can be considered, particularly in patients with DPD deficiency who cannot receive 5-FU 1

Second-Line and Beyond

After Platinum Failure (Within 6 Months)

• Nivolumab or pembrolizumab are first-line options for immunotherapy-naïve patients 1
• Median OS with nivolumab: 7.5 months vs 5.1 months with single-agent therapy (including cetuximab) 1

After Both Platinum and Immunotherapy Failure

Cetuximab monotherapy is FDA-approved but has weak evidence 1

• Level III, Grade C recommendation
• Based on single-arm prospective studies, not randomized trials
• Median OS: 5.2-6.1 months 1
• Also consider: taxanes with or without cetuximab, or methotrexate 1

Critical Clinical Considerations

Important caveat: The KEYNOTE-048 trial that established pembrolizumab superiority did not demonstrate whether platinum/5-FU/pembrolizumab improves survival compared to platinum/5-FU/cetuximab specifically in PD-L1-negative patients 1. This represents a knowledge gap.

Regulatory differences:

• FDA approved pembrolizumab + chemotherapy regardless of PD-L1 status
• EMA approved pembrolizumab (with or without chemotherapy) only for CPS ≥1 1

Toxicity profile of EXTREME regimen:

• Grade 3-5 adverse events: 85.1% 1
• Most common: anemia (13%), neutropenia (22%), thrombocytopenia (11%)
• Sepsis: 9% (vs 1% chemotherapy alone, p=0.02) 2
• Grade 3 skin reactions: 9% 2

Prognostic factors with cetuximab therapy (from recent real-world data):

• Chronic kidney disease, oral cavity primary site, progressive disease as best response, and absence of grade 1-2 cetuximab-related dermatologic toxicity are independent adverse prognostic factors 3
• The presence of mild cetuximab-related skin toxicity paradoxically correlates with better outcomes 3

Practical Treatment Selection

Use cetuximab-based therapy when:

1. PD-L1 testing shows CPS <1
2. Contraindications to anti-PD-1 therapy exist
3. Patient is fit enough for platinum-based chemotherapy
4. As salvage therapy after progression on both platinum and immunotherapy (though evidence is weak)

Avoid cetuximab when:

1. PD-L1 CPS ≥1 and patient can receive pembrolizumab
2. Patient is unfit for platinum-based chemotherapy (consider pembrolizumab monotherapy if PD-L1+)
3. As monotherapy in first-line setting (inferior to combination regimens)

Common pitfall: Do not substitute cetuximab for cisplatin in curative-intent chemoradiation for oropharyngeal cancer, even in HPV-positive disease—this results in inferior survival 4, 5, 6.